Best Sellers
AOD 9604
Price range: £39.99 through £69.99mgAOD-9604
AOD-9604 is a modified C-terminal fragment of human growth hormone developed to isolate lipolytic properties without stimulating IGF-1 or producing the anabolic side effects of full-length GH. Received GRAS status from the FDA as a food additive ingredient.
BPC-157
£64.99mg
High Fragment 196-191 pure fine peptide powder
£64.99mg
NAD+
£555.99mgRetatrutide (Pen)
Price range: £54.99 through £124.99Retatrutide
Metabolics & GLP-1 — Triple Agonist
GIP/GLP-1/GCG triple agonist peptide
Retatrutide is an investigational once-weekly triple agonist of the GIP, GLP-1, and glucagon receptors (triple G). In the Phase II SURMOUNT dose-finding trial, 12 mg weekly produced mean body weight loss of 24.2% at 48 weeks — the highest reported for any pharmacological agent in a controlled trial.
Mechanism:
GIP + GLP-1 + glucagon triple agonist
Stage:
Phase III trials (as of 2026)
Peak Phase II Weight Loss:
24.2% at 48 weeks
SLU-PP-332
£79.99SLU-PP-332
Metabolic — Exercise Mimetic / ERR Agonist
Synthetic ERRα/β/γ pan-agonist · small molecule
SLU-PP-332 is a first-in-class synthetic pan-agonist of the oestrogen-related receptor (ERR) family — ERRα, ERRβ, and ERRγ. Developed at Saint Louis University, it activates the same nuclear receptor transcription factors as aerobic exercise, producing measurable improvements in endurance, fat oxidation, and metabolic health in preclinical models without physical activity. It represents one of the most promising “exercise mimetic” compounds in current research.
Class
ERRα/β/γ pan-agonist — small molecule
Developer
Saint Louis University (Bhatt lab)
Stage
Preclinical — 2023/24 landmark studies
